Treatment of cancer using a CD33 chimeric antigen receptor
AssigneesNovartis AG, The Trustees of the University of Pennsylvania
InventorsHilmar Erhard Ebersbach, Thomas Huber, Julia Jascur, Celeste Richardson, Reshma Singh, Huijuan Song, Qilong Wu, Jiquan Zhang
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for treating diseases associated with expression of CD33. The invention also relates to chimeric antigen receptor (CAR) specific to CD33, vectors encoding the same, and recombinant T cells comprising the CD33 CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises a CD33 binding domain.
Claims24
An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the encoded CAR comprises a CD33 binding domain, a transmembrane domain, and an intracellular signaling domain, and wherein said CD33 binding domain comprises:
- a heavy chain variable region comprising:
- a heavy chain complementarity determining region 1 (HC CDR1) comprising the amino acid sequence of SEQ ID NO:
- 274, a heavy chain complementarity determining region 2 (HC CDR2) comprising the amino acid sequence of SEQ ID NO:
- 283, and a heavy chain complementarity determining region 3 (HC CDR3) comprising the amino acid sequence of SEQ ID NO:
- 292;
- and
- a light chain variable region comprising:
- a light chain complementarity determining region 1 (LC CDR1) comprising the amino acid sequence of SEQ ID NO:
- 301, a light chain complementarity determining region 2 (LC CDR2) comprising the amino acid sequence of SEQ ID NO:
- 310, and a light chain complementarity determining region 3 (LC CDR3) comprising the amino acid sequence of SEQ ID NO:
- 319.
Dependencies are inferred from the claim text.